New Focus on Quantitative Assessment of Response to Therapy in Oncology Imaging

LMS applications provide quantitative assessment of response to therapy with automatic generation of RECIST (Response Evaluation Criteria In Solid Tumors) reports for oncology patients and computer-aided detection (CAD) and follow-up of indeterminate lung nodules. They are integrated with radiology information system/picture archiving and communication systems (RIS/PACS) for an optimized clinical workflow. Median presented this new release at the European Congress of Radiology (ECR), held in March 2009 in Vienna, Austria.

Median Technologies' (Valbonne [-Sophia Antipolis], France) LMS-Lung and LMS-Liver empower the clinicians to increase standards of cancer patient care through the communication of comprehensive follow-up reports containing quantitative information about lesion growth and allowing a better assessment of response to therapy. Those reports can be performed according to the RECIST criteria typically used for clinical trials. Also included in LMS-Lung is a CAD function for a more reliable diagnosis of lung nodules.

"Cancer patient management today suffers from a lack of coordination between the medical specialties and because oncology imaging reporting relies on qualitative instead of quantitative assessment of response to therapy,” explained Fredrik Brag, CEO of Median Technologies. "Our Lesion Management Solutions offer ways to standardize this reporting across cancer care networks for all patients thanks to their unique integration features.”

LMS applications can indeed be integrated with RIS/PACS, included in multi-site configurations, as it has been done recently in Brussels. Such integration optimizes the clinical workflow and communication between radiologists and oncologists and other referring physicians. For cancer patients, this means a more even and standardized management, with the additional benefit of a precise follow-up evaluation based on quantitative data.

RECIST is a set of published rules that define when cancer patients improve (respond), stay the same (stable), or worsen (progression) during treatments.

Median Technologies develops and markets clinical applications for oncology imaging. The company's product line, Median LMS, is a range of clinical applications for the management of cancerous or suspicious lesions diagnosed in computed tomography (CT) imaging scans. LMS applications feature LMS-Lung and LMS-Liver.

Related Links:
Median Technologies